NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Neuropace, Inc. NPCE
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$100.0M
▲ 25.1% vs FY2024
EPS · FY25
$-0.66
Dividend / sh · FY25
$0.00
Payout · FY25
—
ROE · FY25
-158.7%
Net margin · FY25
-21.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 100.0M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 21 cents on every revenue dollar this year.
Per share
USD -0.66
Diluted EPS, FY2025
EPS
Dividend
The company pays no cash dividend.
Profitability
-158.7%
Return on equity, FY2025
ROE
Operating margin-16.3%
Net margin-21.5%
Return on assets-21.4%
Each USD of equity lost 159 cents this year.
Returned to shareholders
USD 49.5M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 49.5M
Share of profit-230.8%
Consecutive raises—
USD 49.5M in buybacks went back to shareholders in a year without profit.
Growth
+19.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+30.0%
+19.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 105.6M
total assets, end of FY2025
Total assetsUSD 105.6M
EquityUSD 19.0M
CashUSD 21.7M
Gross debtUSD 58.9M
Net debtUSD 37.2M
Current ratio5.28×
Net debt stands at 195% of equity.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.1
0.1
0.1
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.66
−0.93
−1.27
−1.91
−2.17
−117.85
Dividend / sh $
0.00
0.00
0.00
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−158.7
−189.4
−118.9
−87.0
·
·
Shares out B
0.03
0.03
0.03
0.03
0.02
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
24 of 24
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed